Karyopharm Therapeutics Inc.
Símbolo: KPTI
NASDAQ
1.37
USDPrecio de mercado actual
-0.9064
Ratio PER
-0.0160
Ratio PEG
157.64M
Capitalización MRK
- 0.00%
Rendimiento DIV
Karyopharm Therapeutics Inc. (KPTI) Estados Financieros
Balance de situación
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 897.57 | 192.1 | 278 | 228.6 | |||||||||||||
balance-sheet.row.short-term-investments | 636.07 | 139.2 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.net-receivables | 132.37 | 27 | 47.1 | 22.5 | |||||||||||||
balance-sheet.row.inventory | 13.65 | 3 | 4.2 | 4.1 | |||||||||||||
balance-sheet.row.other-current-assets | 226.73 | 11.8 | 19.8 | 2.9 | |||||||||||||
balance-sheet.row.total-current-assets | 1069.53 | 233.9 | 326.8 | 258.1 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 23.05 | 4.9 | 7.4 | 1.6 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-investments | 1.7 | 0.3 | 0.6 | 0.6 | |||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.other-non-current-assets | 39.74 | 1.3 | 23.4 | 44.9 | |||||||||||||
balance-sheet.row.total-non-current-assets | 64.5 | 6.5 | 31.4 | 47.2 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.account-payables | 15.4 | 3.1 | 2.8 | 1.6 | |||||||||||||
balance-sheet.row.short-term-debt | 12.56 | 3.3 | 2.9 | 2.3 | |||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.long-term-debt-total | 686.92 | 170.9 | 170.1 | 169.3 | |||||||||||||
Deferred Revenue Non Current | 530.39 | 132.5 | 132.7 | 133 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -395.13 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 172.27 | 63 | 60.3 | 0.7 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 1358.64 | 307.2 | 374.8 | 385 | |||||||||||||
balance-sheet.row.other-liabilities | -123.63 | 0 | -65.9 | -73.7 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 25.52 | 2.8 | 9 | 11.3 | |||||||||||||
balance-sheet.row.total-liab | 1487.05 | 376.6 | 374.8 | 385 | |||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 0.05 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.retained-earnings | -5721 | -1487 | -1343.9 | -1178.6 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.1 | -0.2 | -0.6 | 0.2 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5370.03 | 1351 | 1327.9 | 1098.8 | |||||||||||||
balance-sheet.row.total-stockholders-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1134.03 | 240.4 | 358.2 | 305.3 | |||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-equity | -353.02 | -136.2 | -16.7 | -79.7 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1134.03 | - | - | - | |||||||||||||
Total Investments | 636.37 | 139.5 | 142.8 | 38.2 | |||||||||||||
balance-sheet.row.total-debt | 696.11 | 177 | 173 | 169.3 | |||||||||||||
balance-sheet.row.net-debt | 434.6 | 124.1 | 37.8 | -21.2 |
Estado de tesorería
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 | |||||||||||||
cash-flows.row.depreciation-and-amortization | 0.53 | 0.5 | 0.6 | 0.8 | |||||||||||||
cash-flows.row.deferred-income-tax | 5.92 | -1.1 | 0 | 1.5 | |||||||||||||
cash-flows.row.stock-based-compensation | 21.71 | 21.7 | 35.4 | 29.8 | |||||||||||||
cash-flows.row.change-in-working-capital | 31.41 | 31.4 | -20 | -23.2 | |||||||||||||
cash-flows.row.account-receivables | 20.12 | 20.1 | -5.1 | -9.6 | |||||||||||||
cash-flows.row.inventory | 1.18 | 1.2 | -0.1 | -1.5 | |||||||||||||
cash-flows.row.account-payables | 0.35 | 0.3 | 1.2 | -2.8 | |||||||||||||
cash-flows.row.other-working-capital | -0.7 | 9.8 | -16 | -9.3 | |||||||||||||
cash-flows.row.other-non-cash-items | -9.19 | -2.2 | -0.3 | 8.1 | |||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -92.72 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 104.3 | 5.5 | |||||||||||||
cash-flows.row.purchases-of-investments | -159.15 | -159.2 | -226 | -45.2 | |||||||||||||
cash-flows.row.sales-maturities-of-investments | 167.09 | 167.1 | 121.9 | 192.8 | |||||||||||||
cash-flows.row.other-investing-activites | -18.9 | 0 | -104.3 | -5.5 | |||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 7.94 | 7.9 | -104.3 | 141.8 | |||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | -60 | |||||||||||||
cash-flows.row.common-stock-issued | 1.12 | 1.1 | 189.8 | 9.9 | |||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||
cash-flows.row.other-financing-activites | 1.12 | 1.1 | 4 | 123.7 | |||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 39.69 | 1.1 | 193.7 | 73.6 | |||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.03 | 0 | -0.5 | 0 | |||||||||||||
cash-flows.row.net-change-in-cash | -83.61 | -83.4 | -60.6 | 108.3 | |||||||||||||
cash-flows.row.cash-at-end-of-period | 264.86 | 52.9 | 136.9 | 197.4 | |||||||||||||
cash-flows.row.cash-at-beginning-of-period | 348.48 | 136.3 | 197.4 | 89.1 | |||||||||||||
cash-flows.row.operating-cash-flow | -92.72 | -92.7 | -149.6 | -107.1 | |||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -5.7 | |||||||||||||
cash-flows.row.free-cash-flow | -92.72 | -92.7 | -149.7 | -112.8 |
Fila de la Cuenta de Resultados
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 146.03 | 146 | 157.1 | 209.8 | |||||||||||||
income-statement-row.row.cost-of-revenue | 5.02 | 5.5 | 5.2 | 3.4 | |||||||||||||
income-statement-row.row.gross-profit | 141.01 | 140.6 | 151.9 | 206.4 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 138.67 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 131.88 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.operating-expenses | 270.55 | 270.1 | 294.1 | 304.7 | |||||||||||||
income-statement-row.row.cost-and-expenses | 275.57 | 275.6 | 299.3 | 308.1 | |||||||||||||
income-statement-row.row.interest-income | 10.94 | 10.9 | 2.4 | 0.6 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -0.36 | -0.4 | -0.1 | -0.1 | |||||||||||||
income-statement-row.row.total-operating-expenses | -6.95 | -13.2 | -22.7 | -25.5 | |||||||||||||
income-statement-row.row.interest-expense | 23.82 | 23.8 | 25 | 26 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 5.58 | 0.5 | 2.3 | 0.5 | |||||||||||||
income-statement-row.row.ebitda-caps | -121.1 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -129.54 | -129.5 | -142.2 | -98.3 | |||||||||||||
income-statement-row.row.income-before-tax | -142.78 | -142.8 | -164.9 | -123.8 | |||||||||||||
income-statement-row.row.income-tax-expense | 0.32 | 0.3 | 0.4 | 0.3 | |||||||||||||
income-statement-row.row.net-income | -143.1 | -143.1 | -165.3 | -124.1 |
Preguntas frecuentes
Cuánto es Karyopharm Therapeutics Inc. (KPTI) activos totales?
Karyopharm Therapeutics Inc. (KPTI) los activos totales son 240438000.000.
¿Cuáles son los ingresos anuales de la empresa?
Los ingresos anuales son 69756000.000.
¿Cuál es el margen de beneficios de la empresa?
El margen de beneficios de la empresa es 0.966.
¿Qué es el flujo de caja libre de la empresa?
El flujo de caja libre es -0.808.
¿Cuál es el margen de beneficio neto de la empresa?
El margen de beneficio neto es -0.980.
¿Cuáles son los ingresos totales de la empresa?
Los ingresos totales son -0.887.
¿Qué es Karyopharm Therapeutics Inc. (KPTI) beneficio neto (ingresos netos)?
El beneficio neto (ingresos netos) es -143099000.000.
¿Cuál es la deuda total de la empresa?
La deuda total es 177016000.000.
¿Cuál es la cifra de gastos de explotación?
Los gastos de explotación son 270101000.000.
¿Cuál es la cifra de tesorería de la empresa?
La tesorería de la empresa es 52891000.000.